Denis C, Denis J
Département de Biologie, Unité de Microbiologie, Hôpital Gilles de Corbeil, Corbeil-Essonnes.
Presse Med. 1988 Jan 30;17(3):111-4.
The pharmacokinetics of netilmicin after intramuscular injection (2 mg/kg) was investigated comparatively in cirrhotic patients with or without ascites, and in healthy subjects. In patients with ascites, the same pharmacokinetic parameters were measured after the ascites had been cured. Twenty-four hours after intramuscular injection, the residual levels in cirrhotic patients were moderately higher than in controls, showing that liver failure or ascites did not significantly modify the pharmacokinetics of netilmicin. Serum concentrations were bactericidal. The ascitic fluid level was lower than the therapeutic range, but it was sustained for nearly 24 hours after intraperitoneal injection (2 mg/kg). These results indicate that netilmicin may be administered to cirrhotic patients without peritoneal infection using the same regimen as in healthy subjects. The peritoneal route may be preferable in case of peritoneal infection.
对有或无腹水的肝硬化患者以及健康受试者进行了比较研究，观察了奈替米星肌肉注射（2mg/kg）后的药代动力学。对于有腹水的患者，在腹水治愈后测量相同的药代动力学参数。肌肉注射24小时后，肝硬化患者体内的残留水平略高于对照组，表明肝功能衰竭或腹水并未显著改变奈替米星的药代动力学。血清浓度具有杀菌作用。腹水液中的浓度低于治疗范围，但在腹腔注射（2mg/kg）后可维持近24小时。这些结果表明，对于无腹膜感染的肝硬化患者，可采用与健康受试者相同的给药方案使用奈替米星。对于腹膜感染的情况，腹腔给药途径可能更可取。
